Adimab Expands Research Agreement with Regeneron

May 8, 2019 Off By BusinessWire

LEBANON, N.H.–(BUSINESS WIRE)–Adimab,
LLC
, the leading provider of antibody discovery and optimization
technology, today announced the expansion of an earlier multi-target
research agreement with Regeneron Pharmaceuticals.

Adimab and Regeneron commenced an initial agreement in December 2014,
under which Adimab committed to build a custom common light chain
antibody library uniquely for Regeneron and to discover and optimize
antibodies against six targets chosen by Regeneron. Thus far, Regeneron
has exercised its option for commercial rights to antibodies against one
of the six targets. These antibodies are currently undergoing further
preclinical research. Under the expanded agreement, Adimab will discover
and/or optimize antibodies against six additional targets, and Regeneron
will have the right to develop and commercialize any therapeutic program
resulting from the collaboration.

“Regeneron is clearly one of the leading biopharma companies in the
industry,” said Tillman Gerngross, CEO and Co-Founder of Adimab.
“Regeneron was very sophisticated in how they leveraged our unique
antibody engineering capabilities which may enable therapeutic
development against traditionally difficult-to-address targets. We are
looking forward to an expanded partnership with this science-minded
company.”

Under the terms of the agreement, Adimab will use its proprietary
yeast-based antibody platform to discover and/or optimize fully human
antibodies against up to six additional Regeneron-selected targets.
Adimab will receive near-term research fees for each target and is
entitled to certain delivery milestones. In addition, for each target,
Regeneron will have an option to commercialize antibodies generated
during the collaboration, for which Adimab would receive option exercise
fees, clinical milestones and royalties on any potential product sales.

About Adimab

Adimab is the leading technology provider for antibody-based drug
discovery, focusing solely on its partners without pursuing an internal
product pipeline. Since 2009, Adimab has partnered with 65
pharmaceutical and biotechnology companies, generating more than 280
therapeutic programs. The Adimab technology has been transferred and
implemented at Biogen, GSK, Lilly, Merck, and Novo Nordisk. Funded
discovery partners include leading pharmaceutical companies, such as
Boehringer Ingelheim, Celgene, Genentech, Gilead, Kyowa Hakko Kirin,
Novartis, Roche, Sanofi, Takeda and others. Adimab has also partnered
with many early-stage venture-backed companies, including Alector,
Cullinan Oncology, Dragonfly, Pliant, Potenza, Tizona, iTeos and others,
as well as mid-size public biopharmaceutical companies such as
Acceleron, Five Prime, Innovent, Jounce, Mersana, Scholar Rock, Seattle
Genetics, Surface Oncology, and others.

Adimab’s integrated antibody discovery and engineering platform provides
unprecedented speed from antigen to purified, full-length human IgGs.
Adimab offers fundamental advantages by delivering diverse panels of
therapeutically relevant antibodies that meet the most aggressive
standards for affinity, epitope coverage, species cross-reactivity, and
developability. Adimab enables its partners to rapidly expand their
biologics pipelines through a broad spectrum of technology access
arrangements. For more information, visit http://www.adimab.com.

Contacts

Guy Van Meter
Chief Business Officer
Adimab, LLC
(603)
653-5775